We are monitoring the impact of COVID-19 on Europe Kidney Cancer Diagnostics and Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date August, 2019
ID: 787
Share on
Share on

Europe Kidney Cancer Diagnostics and Therapeutics Market Research Report - Segmented By Type, Tests & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe) - Industry Analysis, Size, Share, Growth, Trends and Forecast (2019 - 2024)

Pulished: August, 2019
ID: 787
Pages: 133

Europe Kidney Cancer Diagnostics and Therapeutics Market Size & Growth (2019 - 2024)

The size of the Kidney Cancer Diagnostics and Therapeutics Market in Europe was worth USD 0.87 billion in 2019 and estimated to be growing at a CAGR of 5.74%, to reach USD 1.15 billion by 2024.

Though there has been extensive progress in science and technology to tackle cancer, it continues to threaten lives across the world.

Kidney cancer is one of the recurrent urologic tumours accounting for around 3% of all the human cancers. The occurrence rate of renal cell carcinoma has increased progressively in recent decades.

Rise in Kidney cancer screening tests is one of the major drivers for the Kidney Cancer Diagnostics and Therapeutics market in this region. Another aspect is that European countries face comparable economic and demographic burdens and share an interest in scrutinizing their impact on health outcomes nationally and across Europe.

However, the high cost of Kidney cancer treatment is one of the main factors hindering the growth of this market in this region.

This research report segmented and sub-segmented into the following categories:

  • By Type: Transitional Cell Cancer, Renal Cell Carcinoma, Renal Sarcoma and Others
  • By Tests: Biopsy, CT Scan, Cystoscopy, Intravenous Pyelogram and Kidney Ultrasound
  • By Country: UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe

On the basis of tests type, the Biopsy and CT Scan lead the tests segment in the Kidney Cancer Diagnostics and Therapeutics market accounting for more than 50% of the market.

Regionally, European is the third-largest market with a global share of 25%. The UK is the largest market shareholder for the Kidney Cancer Diagnostics and Therapeutics market in this region, followed by Germany and France.

Key players operating in the Europe America Kidney Cancer Diagnostics and Therapeutics Market profiled in this report are GlaxoSmithKline, Bayer, Pfizer, Sanofi S.A, Hoffmann La Roche, Novartis and Abbott Laboratories.

1.Introduction                              

              1.1 Market Definition                  

              1.2 Study Deliverables                

              1.3 Base Currency, Base Year and Forecast Periods                       

              1.4 General Study Assumptions              

2. Research Methodology                                       

              2.1 Introduction                           

              2.2 Research Phases                    

                             2.2.1 Secondary Research          

                             2.2.2 Primary Research

                             2.2.3 Econometric Modelling     

                             2.2.4 Expert Validation 

              2.3 Analysis Design                      

              2.4 Study Timeline                       

3. Overview                                   

              3.1 Executive Summary              

              3.2 Key Inferences                       

              3.3 New Developments              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                

              4.1 Market Drivers                       

              4.2 Market Restraints                  

              4.3 Key Challenges                       

              4.4 Current Opportunities in the Market                           

5. Market Segmentation                                          

              5.1 By Type                     

                             5.1.1 Transitional Cell Cancer    

                             5.1.2 Renal cell carcinoma         

                             5.1.3 Renal sarcoma     

                             5.1.4 Other Cancers      

              5.2 By Tests                     

                             5.2.1 Biopsy      

                             5.2.2 CT Scan    

                             5.2.3 Cystoscopy            

                             5.2.4 Intravenous pyelogram    

                             5.2.5 Kidney Ultrasound             

6. Geographical Analysis                                         

              6.1 Introduction                           

              6.2 U.K               

              6.3 Spain                          

              6.4 Germany                   

              6.5 Italy                            

              6.6 France                       

7. Pipeline Product Analysis                                    

              7.1 Overview                                 

              7.2 Pipeline Development Landscape                                 

              7.3 Molecular Targets in the Pipeline                                  

              7.4 Clinical Trials                          

                             7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target    

                             7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target             

                             7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.   

8.Strategic Analysis                                    

              8.1 PESTLE analysis                      

                             8.1.1 Political    

                             8.1.2 Economic

                             8.1.3 Social       

                             8.1.4 Technological       

                             8.1.5 Legal         

                             8.1.6 Environmental     

              8.2 Porter’s Five analysis                          

                             8.2.1 Bargaining Power of Suppliers       

                             8.2.2 Bargaining Power of Consumers   

                             8.2.3 Threat of New Entrants    

                             8.2.4 Threat of Substitute Products and Services             

                             8.2.5 Competitive Rivalry within the Industry     

9.Market Leaders' Analysis                                     

              9.1 GlaxoSmithKline                    

                             9.1.1 Overview 

                             9.1.2 Product Analysis  

                             9.1.3 Strategic Evaluation and Operations          

                             9.1.4 Financial analysis 

                             9.1.5 Legal issues           

                             9.1.6 Recent Developments       

                             9.1.7 SWOT analysis      

                             9.1.8 Analyst View         

              9.2 Bayer                         

              9.3 Pfizer                         

              9.4 Sanofi S.A                 

              9.5 Hoffmann La Roche              

              9.6 Novartis                    

              9.7 Abbott Laboratories                            

10.Competitive Landscape                                      

              10.1 Market share analysis                      

              10.2 Merger and Acquisition Analysis                  

              10.3 Agreements, collaborations and Joint Ventures                    

              10.4 New Product Launches                     

11.Expert Opinions                                    

              11.1 Market Outlook                   

              11.2 Investment Opportunities               

Appendix                                       

              a) List of Tables              

              b) List of Figures                           

  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Kidney Cancer Diagnostics and Therapeutics Market By Region, From 2019-2024 (USD Billion)
  2. Europe Kidney Cancer Diagnostics and Therapeutics Market By Type, From 2019-2024 (USD Billion)
  3. Europe Transitional Cell Cancer Market By Region, From 2019-2024 (USD Billion)
  4. Europe Renal cell carcinoma Market By Region, From 2019-2024 (USD Billion)
  5. Europe Renal sarcoma Market By Region, From 2019-2024 (USD Billion)
  6. Europe Other Kidney Cancers Market By Region, From 2019-2024 (USD Billion)
  7. Europe Kidney Cancer Diagnostics and Therapeutics Market By Tests, From 2019-2024 (USD Billion)
  8. Europe Biopsy Market By Region, From 2019-2024 (USD Billion)
  9. Europe CT Scan Market By Region, From 2019-2024 (USD Billion)
  10. Europe Cystoscopy Market By Region, From 2019-2024 (USD Billion)
  11. Europe Intravenous pyelogram Market By Region, From 2019-2024 (USD Billion)
  12. Europe Kidney Ultrasound Market By Region, From 2019-2024 (USD Billion)
  13. U.K Kidney Cancer Diagnostics and Therapeutics Market By Type, From 2019-2024 (USD Billion)
  14. U.K Kidney Cancer Diagnostics and Therapeutics Market By Tests, From 2019-2024 (USD Billion)
  15. Spain Kidney Cancer Diagnostics and Therapeutics Market By Type, From 2019-2024 (USD Billion)
  16. Spain Kidney Cancer Diagnostics and Therapeutics Market By Tests, From 2019-2024 (USD Billion)
  17. Germany Kidney Cancer Diagnostics and Therapeutics Market By Type, From 2019-2024 (USD Billion)
  18. Germany Kidney Cancer Diagnostics and Therapeutics Market By Tests, From 2019-2024 (USD Billion)
  19. Italy Kidney Cancer Diagnostics and Therapeutics Market By Type, From 2019-2024 (USD Billion)
  20. Italy Kidney Cancer Diagnostics and Therapeutics Market By Tests, From 2019-2024 (USD Billion)
  21. France Kidney Cancer Diagnostics and Therapeutics Market By Type, From 2019-2024 (USD Billion)
  22. France Kidney Cancer Diagnostics and Therapeutics Market By Tests, From 2019-2024 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample